"NewPro" Raises Tens of Millions of RMB in Pre-A Round; Linear Capital Led Angel Round | Linear Portfolio

NewPro recently announced the completion of a Pre-A funding round worth tens of millions of RMB, jointly led by Shanghai SDIC Pioneer Fund and Aochuang Pioneer Fund.

The company specializes in synthetic biology technology, relying on its advanced industrial chassis engineering system FlexBaseTM and intelligent precision fermentation process NeuroBrewTM to focus on the biomanufacturing of scarce functional proteins found in nature.

Linear Capital was the lead investor in NewPro's angel round. Building on a solid foundation for the commercialization of lactoferrin, the company continues to develop multiple high-value functional food protein pipelines including osteopontin and ovalbumin.

Recently, NewPro Bioworks (Shanghai Newpro Biosciences Co., Ltd.) announced the completion of a Pre-A funding round worth tens of millions of RMB. This round was jointly led by Shanghai SDIC Pioneer Fund and Aochuang Pioneer Fund. The latter was co-founded by Dalton Venture and listed industry player OPM Biosciences, making it the first biomanufacturing industry CVC fund in the Yangtze River Delta region. At the same time, the company's self-developed precision fermentation lactoferrin product has officially received FDA Self-GRAS (Generally Recognized as Safe) certification in the United States, marking a critical breakthrough in international market access for its core product.

This investment fully demonstrates capital markets' strong recognition of innovative applications of synthetic biology in the food sector, and represents firm confidence in NewPro Bioworks' technical moat, product execution capabilities, and long-term growth value.

The proceeds from this round will be primarily directed toward three areas: first, accelerating the regulatory approval process for lactoferrin as a new food ingredient in China; second, deepening overseas market expansion and driving commercialization of its FDA Self-GRAS certified products in international markets; and third, advancing scaled production capacity for functional food proteins.

NewPro Bioworks is a biomanufacturing company specializing in synthetic biology technology, relying on its advanced industrial chassis engineering system FlexBaseTM and intelligent precision fermentation process NeuroBrewTM to focus on the biomanufacturing of scarce functional proteins found in nature.

Leveraging its self-developed FlexBaseTM industrial chassis engineering system, the company has achieved standardized plug-and-play bioelements for industrial microbial chassis, high-throughput screening combining dry-lab and wet-lab approaches, and dedicated cellular compartmentalization functional remodeling. For example, in the expression and secretion of its core product lactoferrin, FlexBaseTM solves the complex protein modification challenge — particularly deep simulation of glycosylation modifications — thereby ensuring that precision-fermented recombinant proteins are highly consistent with natural proteins. Relying on its intelligent precision fermentation process NeuroBrewTM, NewPro Bioworks has accumulated thousands of batches of fermentation data at pilot scale to form AI-specific data models, and has further achieved intelligent fermentation control and process optimization based on dedicated models at pilot and production scales. This process technology ensures efficient, stable, and low-cost production of functional ingredients such as lactoferrin.

Meanwhile, building on a solid foundation for the commercialization of lactoferrin, the company continues to develop multiple high-value functional food protein pipelines including osteopontin and ovalbumin, committed to leveraging advanced biomanufacturing technology to create safe, high-quality, and sustainable innovative food ingredient solutions, and driving the industrial adoption of synthetic biology technology in consumer applications.